Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients
Open accessAbstract
In contrast to immunocompetent participants in vaccine trials, 1,2 a low proportion (17%) of solid organ transplant recipients mounted a positive antibody response to the first dose of SARS-CoV-2 messenger RNA (mRNA) vaccines, with those receiving anti-metabolite maintenance immunosuppression less likely to respond. 3 In this study, we assessed antibody response after the second dose.Methods | Transplant recipients without prior polymerase chain reaction-confirmed COVID-19 were recruited from across the US to participate in this prospective cohort through a digital campaign.Those who completed the 2-dose SARS-CoV-2 mRNA vaccine series between December 16, 2020, and March 13, 2021, were included and followed up through April 13, 2021.As described previously, 3 semiquantitative antispike serologic testing was undertaken with the Roche Elecsys anti-SARS-CoV-2 S enzyme immunoassay, positive cutoff of at least 0.8 U/mL, which tests for the receptor-binding domain of the SARS-CoV-2 spike protein, 2204
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Participants with immunosuppression had consistently lower antibody responses, with neutralizing antibody titers five times lower than those without immunosuppression.
“Similar to the findings in other reports,17-19 a significantly lower antibody response was found consistently through the observation period among participants with immunosuppression, who had neutralizing antibody titers that were lower by a factor of 5 than those among participants without immunosuppression.”
From Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months (2021) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237 · see citing works
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615 · see citing works
Boyarsky, B. J., Werbel, W. A., Avery, R. K., Tobian, A. A. R., Massie, A. B., Segev, D. L., & Garonzik‐Wang, J. (2021) · JAMA · doi:10.1001/jama.2021.4385 · Cited by 507 · see citing works
Self-citationKlein, S. L., Pekosz, A. S., Park, H.-S., Ursin, R. L., Shapiro, J. R., Benner, S. E., Littlefield, K. E., Kumar, S., Naik, H. M., Betenbaugh, M. J., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci142004 · Cited by 424 · see citing works
Self-citationPatel, E. U., Bloch, E. M., Clarke, W. A., Hsieh, Y., Boon, D., Eby, Y. J., Fernández, R. E., Baker, O. R., Keruly, M., Kirby, C. S., et al. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.02257-20 · Cited by 185 · see citing works
Self-citationMueller, T. (2021) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.03.007 · Cited by 36 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. 2020;383(25):2439-2450. doi:10.1056/NEJMoa2027906 · DOI · Paper page
Cited by
Sorted by citations
Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
Levin, E. G., Lustig, Y., Cohen, C., Fluss, R., Indenbaum, V., Amit, S., Doolman, R., Asraf, K., Mendelson, E., Ziv, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114583 · Cited by 1,703 · see citing works
Accelerated COVID-19 vaccine development: milestones, lessons, and prospects
Bok, K., Sitar, S., Graham, B. S., & Mascola, J. R. (2021) · Immunity · doi:10.1016/j.immuni.2021.07.017 · Cited by 254 · see citing works
Abe, K. T., Hu, Q., Mozafarihashjin, M., Samson, R., Manguiat, K., Robinson, A., Rathod, B., Hardy, W. R., Wang, J. H., Iskilova, M., et al. (2021) · doi:10.1101/2021.08.06.21261721 · Cited by 32 · see citing works
Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals
Lederer, K., Parvathaneni, K., Painter, M. M., Bettini, E., Agarwal, D., Lundgreen, K. A., Weirick, M., Goel, R. R., Xu, X., Drapeau, E. M., et al. (2021) · doi:10.1101/2021.09.16.21263686 · Cited by 179 · see citing works
Haidar, G., Agha, M., Lukanski, A., Linstrum, K., Troyan, R., Bilderback, A., Rothenberger, S., McMahon, D. K., Crandall, M., Enick, P. N., et al. (2021) · doi:10.1101/2021.06.28.21259576 · Cited by 126 · see citing works
- Authors
- Boyarsky, B. J., Werbel, W. A., Avery, R. K., Tobian, A. A. R., Massie, A. B., Segev, D. L., & Garonzik-Wang, J. M.
- Affiliations
- Johns Hopkins University (US)
- Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland
- ORCID
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2021-06-01
- Volume
- 325
- Issue
- 21
- Pages
- 2204
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC8100911
- OpenAlex
- W3158948419
- Cited by
- 955
- References
- 6
- Citations by year
- 2026: 18 · 2025: 44 · 2024: 87 · 2023: 135 · 2022: 372 · 2021: 297 · 2012: 1
- FWCI
- 70.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (K24AI144954)
- National Institute of Diabetes and Digestive and Kidney Diseases (F32DK124941, K23DK115908, K01DK101677)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- COVID-19 mRNA vaccine, solid organ transplant recipients, antibody response, immunosuppression, anti-spike antibodies, COVID-19 vaccination, vaccine immunogenicity
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, Adolescent, Adult, Antibodies, Viral, Female, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Organ Transplantation, Young Adult, Spike Glycoprotein, Coronavirus, Transplant Recipients
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
